3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
55
Carcinoma, Hepatocellular
54
Lung Neoplasms
32
Small Cell Lung Carcinoma
28
Neoplasms
25
Breast Neoplasms
20
Colorectal Neoplasms
18
Melanoma
15
Urinary Bladder Neoplasms
13
Triple Negative Breast Neoplasms
13
Carcinoma, Transitional Cell
13
Neoplasm Metastasis
12
Carcinoma, Renal Cell
12
Squamous Cell Carcinoma of Head and Neck
10
Prostatic Neoplasms
9
Uterine Cervical Neoplasms
8
Glioblastoma
8
Stomach Neoplasms
7
Endometrial Neoplasms
7
Ovarian Neoplasms
6
Head and Neck Neoplasms
6
Sarcoma
5
Pancreatic Neoplasms
5
Carcinoma, Neuroendocrine
5
Carcinoma, Merkel Cell
5
Liver Neoplasms
4
Kidney Neoplasms
4
Extensive Stage Lung Small Cell Carcinoma
4
Carcinoma
4
Brain Neoplasms
4
Interventions
Cyclophosphamide
8
Rituximab
5
fludarabine
4
Vincristine
4
Prednisone
4
Doxorubicin
4
fludarabine phosphate
3
Tacrolimus
3
Mycophenolic Acid
3
Etoposide
3
Busulfan
3
venetoclax
2
entrectinib
2
atezolizumab
2
alectinib
2
acalabrutinib
2
Whole-Body Irradiation
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mesna
2
Melphalan
2
Bortezomib
2
trametinib
1
pertuzumab
1
pembrolizumab
1
obinutuzumab
1
liposomal doxorubicin
1
isatuximab
1
ibrutinib
1
etoposide phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
atezolizumab
×
1 year
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770102
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled